I perform a broad spectrum of common to complex operations in children with excellent outcomes and success with regional expansion. I have led strategic growth and development of world-class, nationally recognized children’s surgical care, including surgical and procedural excellence through the expansion and dissemination of disease-focused multidisciplinary teams that have consistently achieved the highest quality of patient care. My values are aligned with leading and delivering the best quality of patient care, assuring that all children and families achieve optimal health and wellness.

I am involved in basic science and translational research which dovetails with my clinical expertise. My basic science research focuses on investigating human DNA end-joining proteins as therapeutic targets in high-risk neuroblastoma and on optimizing biologically relevant preclinical models for studying the impact of social deprivation on cancer progression. I have assembled an interdisciplinary team including medicinal chemistry, drug design, biochemistry, and veterinary pathology to pursue this line of research and my lab recently obtained independent extramural funding. This is a high-risk high-reward project which has the potential to create a major paradigm shift in the treatment of neuroblastoma.